Table 1.
Participant demographics
| Total sample (N = 32) |
Pain interference (n = 20a) |
Sleep disturbance (n = 12a) |
|
|---|---|---|---|
| Age (years), mean (SD) | 53.9 (10.3) | 53.2 (11.4) | 55.0 (8.5) |
| Age at diagnosis (years), mean (SD) | 42.6 (9.5) | 42.4 (10.5) | 42.9 (8.1) |
| Time since diagnosis (years), mean (SD) | 10.7 (9.4) | 9.2 (7.4) | 13.3 (12.0) |
| Number of swollen joints at screening, mean (SD) | 9.4 (4.4) | 8.5 (4.0) | 10.9 (4.8) |
| Number of tender joints at screening, mean (SD) | 10.2 (6.2) | 8.8 (3.6) | 12.7 (8.8) |
| Female, n (%) | 21 (66) | 13 (65) | 8 (67) |
| Race/ethnicity, n (%) | |||
| White, non-Hispanic | 20 (63) | 14 (70) | 6 (50) |
| Black or African American | 10 (31) | 4 (20) | 6 (50) |
| Asian | 1 (3) | 1 (5) | 0 |
| Other | 1 (3) | 1 (5) | 0 |
| Current RA medication, n (%) | |||
| Biologic only | 1 (3) | 1 (5) | 0 |
| csDMARD only | 13 (41) | 6 (30) | 7 (58) |
| Both biologic and csDMARD | 17 (53) | 12 (60) | 5 (42) |
| Neither biologic nor csDMARDb | 1 (3) | 1 (5) | 0 |
| Self-reported RA severity, n (%) | |||
| Mild | 0 | 0 | 0 |
| Moderate | 22 (69) | 14 (70) | 8 (67) |
| Severe | 10 (31) | 6 (30) | 4 (33) |
csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; RA, rheumatoid arthritis; SD, standard deviation
an values represent the number of participants who took part in cognitive debriefing for each item bank
bOne participant had previously taken a biologic for treatment of RA, but was in the process of switching medications due to reported medication side effects